NO20032703L - Pyrazolforbindelser nyttige som proteinkinaseinhibitorer - Google Patents

Pyrazolforbindelser nyttige som proteinkinaseinhibitorer

Info

Publication number
NO20032703L
NO20032703L NO20032703A NO20032703A NO20032703L NO 20032703 L NO20032703 L NO 20032703L NO 20032703 A NO20032703 A NO 20032703A NO 20032703 A NO20032703 A NO 20032703A NO 20032703 L NO20032703 L NO 20032703L
Authority
NO
Norway
Prior art keywords
protein kinase
kinase inhibitors
compounds useful
pyrazole compounds
pyrazole
Prior art date
Application number
NO20032703A
Other languages
English (en)
Other versions
NO20032703D0 (no
NO328501B1 (no
Inventor
David Bebbington
Jean-Damien Charrier
Julian M C Golec
Andrew Miller
Ronald Knegtel
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20032703D0 publication Critical patent/NO20032703D0/no
Publication of NO20032703L publication Critical patent/NO20032703L/no
Publication of NO328501B1 publication Critical patent/NO328501B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
NO20032703A 2000-12-21 2003-06-13 Pyrazolforbindelser samt anvendelse derav for fremstilling av medikamenter til behandling av lidelser assosiert med Aurora-2-, GSK-3- eller Src-aktivitet NO328501B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25788700P 2000-12-21 2000-12-21
US28694901P 2001-04-27 2001-04-27
PCT/US2001/049401 WO2002057259A2 (en) 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors

Publications (3)

Publication Number Publication Date
NO20032703D0 NO20032703D0 (no) 2003-06-13
NO20032703L true NO20032703L (no) 2003-08-19
NO328501B1 NO328501B1 (no) 2010-03-01

Family

ID=26946273

Family Applications (5)

Application Number Title Priority Date Filing Date
NO20032670A NO328537B1 (no) 2000-12-21 2003-06-12 Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20032671A NO20032671L (no) 2000-12-21 2003-06-12 Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20032704A NO330527B1 (no) 2000-12-21 2003-06-13 Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20032703A NO328501B1 (no) 2000-12-21 2003-06-13 Pyrazolforbindelser samt anvendelse derav for fremstilling av medikamenter til behandling av lidelser assosiert med Aurora-2-, GSK-3- eller Src-aktivitet
NO20032736A NO20032736L (no) 2000-12-21 2003-06-16 Pyrazolforbindelser nyttige som proteinkinaseinhibitorer

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO20032670A NO328537B1 (no) 2000-12-21 2003-06-12 Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20032671A NO20032671L (no) 2000-12-21 2003-06-12 Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20032704A NO330527B1 (no) 2000-12-21 2003-06-13 Pyrazolforbindelser nyttige som proteinkinaseinhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20032736A NO20032736L (no) 2000-12-21 2003-06-16 Pyrazolforbindelser nyttige som proteinkinaseinhibitorer

Country Status (28)

Country Link
US (16) US20030105090A1 (no)
EP (10) EP2264028A1 (no)
JP (19) JP4160395B2 (no)
KR (8) KR100889246B1 (no)
CN (6) CN100408573C (no)
AP (2) AP1588A (no)
AR (4) AR042398A1 (no)
AT (9) ATE326462T1 (no)
AU (7) AU2002234047A1 (no)
BR (2) BR0116411A (no)
CA (8) CA2432303C (no)
CY (1) CY1106297T1 (no)
DE (8) DE60119776T2 (no)
DK (3) DK1355905T3 (no)
ES (7) ES2265446T3 (no)
HK (8) HK1059776A1 (no)
HU (5) HUP0400638A2 (no)
IL (8) IL156369A0 (no)
MX (8) MXPA03005606A (no)
MY (1) MY140377A (no)
NO (5) NO328537B1 (no)
NZ (8) NZ526469A (no)
PL (2) PL210414B1 (no)
PT (3) PT1353916E (no)
RU (1) RU2355688C2 (no)
SI (2) SI1353916T1 (no)
TW (2) TWI290551B (no)
WO (8) WO2002066461A1 (no)

Families Citing this family (371)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982260B1 (en) 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317448B2 (en) 2000-09-15 2011-05-04 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ATE407132T1 (de) * 2000-12-05 2008-09-15 Vertex Pharma Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
JP4160395B2 (ja) * 2000-12-21 2008-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
MY134783A (en) * 2001-03-23 2007-12-31 Bayer Healthcare Llc Rho-kinase inhibitors
EP1379251B1 (en) 2001-04-10 2008-07-09 Merck & Co., Inc. Inhibitors of akt activity
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EA007430B1 (ru) 2001-09-26 2006-10-27 Фармация Италия С.П.А. Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
EP1465610B1 (en) 2002-01-10 2008-12-31 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PL372198A1 (en) * 2002-02-06 2005-07-11 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
US7179826B2 (en) 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
ATE466580T1 (de) 2002-03-15 2010-05-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) * 2002-03-15 2010-07-01 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004009602A1 (en) * 2002-07-23 2004-01-29 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
CN1678321A (zh) 2002-07-29 2005-10-05 里格尔药品股份有限公司 用2,4－嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
EP1739087A1 (en) * 2002-08-02 2007-01-03 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
EP1532145B1 (en) * 2002-08-02 2006-09-13 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
MXPA05001807A (es) 2002-09-05 2005-04-19 Aventis Pharma Sa Nuevos derivados de aminoindazol utilizados como medicamentos y composiciones farmaceuticas que los contienen.
FR2844267B1 (fr) * 2002-09-05 2008-02-15 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
NZ539211A (en) * 2002-10-04 2008-05-30 Prana Biotechnology Ltd Neurologically-active compounds
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
US7309701B2 (en) 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7462613B2 (en) 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
ES2412273T3 (es) 2002-11-21 2013-07-10 Novartis Ag Inhibidores de 2-morfolín-4-pirimidinas como inhibidores de fosfotidilinositol (PI) 3-quinasa y su uso en el tratamiento del cáncer.
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
EP1644338A1 (en) * 2003-04-01 2006-04-12 Aponetics AG 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
ES2374272T3 (es) 2003-06-19 2012-02-15 Glaxosmithkline Llc Derivados de 5-(acilamino)indazol como inhibidores de quinasas.
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
WO2005012256A1 (en) 2003-07-22 2005-02-10 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
AU2004261484A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1656372B1 (en) 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US7417726B2 (en) * 2003-09-19 2008-08-26 Applied Biosystems Inc. Normalization of data using controls
US20060024690A1 (en) * 2003-09-19 2006-02-02 Kao H P Normalization of data using controls
US20050221357A1 (en) * 2003-09-19 2005-10-06 Mark Shannon Normalization of gene expression data
US20050124562A1 (en) * 2003-09-23 2005-06-09 Joseph Guiles Bis-quinazoline compounds for the treatment of bacterial infections
KR20060123164A (ko) 2003-10-17 2006-12-01 아스트라제네카 아베 암 치료에 사용하기 위한 4-(피라졸-3-일아미노)피리미딘유도체
CA2548172A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
WO2005056552A1 (en) * 2003-12-09 2005-06-23 Vertex Pharmaceuticals Incorporated Naphthyridine derivatives and their use as modulators of muscarinic receptors
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7534798B2 (en) 2004-02-11 2009-05-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1723427A2 (en) * 2004-02-26 2006-11-22 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b)
JP4875978B2 (ja) * 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
EP2522670A1 (en) * 2004-04-07 2012-11-14 Takeda Pharmaceutical Company Limited Heterocyclic CRF receptor antagonists
WO2005103010A2 (en) * 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
JP2007533753A (ja) * 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
MXPA06012613A (es) * 2004-05-07 2007-01-31 Amgen Inc Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
SI1771450T1 (sl) * 2004-05-14 2008-06-30 Millennium Pharm Inc Spojine in postopki za inhibiranje mitotične progresije z inhibicijo kinaze Aurora
AU2012200416B2 (en) * 2004-05-14 2014-07-31 Millennium Pharmaceuticals, Inc. "Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
US20050255485A1 (en) * 2004-05-14 2005-11-17 Livak Kenneth J Detection of gene duplications
WO2005111039A2 (en) * 2004-05-14 2005-11-24 Millennium Pharmaceuticals, Inc. Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
BRPI0511124A (pt) * 2004-05-14 2007-11-27 Vertex Pharma pró-drogas de inibidores de erk proteìna cinase de pirrolilpirimidina
WO2005112923A2 (en) * 2004-05-20 2005-12-01 Bayer Pharmaceuticals Corporation 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
US20050282094A1 (en) * 2004-05-27 2005-12-22 Kim Young H Developer for a photopolymer protective layer
CA2571178A1 (en) * 2004-07-01 2006-01-19 Synta Pharmaceuticals Corp. 2-substituted heteroaryl compounds
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
US8946248B2 (en) * 2004-09-30 2015-02-03 Janssen R&D Ireland HIV inhibiting 5-substituted pyrimidines
US7531548B2 (en) * 2004-09-30 2009-05-12 Tibotec Pharmaceuticals Ltd HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
TW200626574A (en) * 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-heterocyclyl pyrimidines
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
WO2006046735A1 (en) * 2004-10-29 2006-05-04 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
EP1809290A2 (en) 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
RU2007122485A (ru) 2004-11-17 2008-12-27 Мийкана Терапьютикс Ингибиторы киназы
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2006067614A2 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
PT1856135E (pt) 2005-01-19 2010-02-26 Rigel Pharmaceuticals Inc Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
WO2006081230A2 (en) * 2005-01-26 2006-08-03 Schering Corporation 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
PT1846394E (pt) 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
DK1853602T3 (da) * 2005-02-16 2010-09-20 Astrazeneca Ab Kemiske forbindelser
BRPI0607455A2 (pt) * 2005-02-16 2009-09-01 Astrazeneca Ab composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
JP2008533145A (ja) * 2005-03-15 2008-08-21 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EP1863797A1 (en) * 2005-03-23 2007-12-12 AstraZeneca AB 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
US7402596B2 (en) * 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
ATE404554T1 (de) * 2005-04-05 2008-08-15 Astrazeneca Ab Pyrimidinderivate zur verwendung als antikrebsmittel
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
BRPI0608178A2 (pt) 2005-04-14 2009-11-17 Hoffmann La Roche derivados de aminopirazol, sua fabricação, composição farmacêutica e uso como agentes farmacêuticos
CN101208093A (zh) * 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
US7928126B2 (en) 2005-04-28 2011-04-19 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP1885369B1 (en) 2005-05-04 2015-09-23 Evotec AG Fused heterocyclic compounds, and compositions and uses thereof
US20080194606A1 (en) * 2005-05-05 2008-08-14 Astrazeneca Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer
EP1899323A2 (en) * 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
SG137989A1 (en) 2005-06-08 2008-01-28 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK pathway
WO2006138304A2 (en) 2005-06-14 2006-12-28 Taigen Biotechnology Pyrimidine compounds
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
JP2009504771A (ja) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド ピラジンキナーゼ阻害剤
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
KR20140025610A (ko) * 2005-09-30 2014-03-04 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
CN101316587B (zh) * 2005-09-30 2013-04-03 迈卡纳治疗股份有限公司 取代的吡唑化合物
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
PT1945631E (pt) 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007053345A1 (en) * 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
JP5249771B2 (ja) * 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
ATE508126T1 (de) * 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
WO2007081978A2 (en) * 2006-01-11 2007-07-19 Angion Biomedica Corporation Modulators of hepatocyte growth factor / c-met activity
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
ATE485268T1 (de) 2006-02-16 2010-11-15 Schering Corp Pyrrolidin-derivate als erk-hemmer
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
CA2645958C (en) 2006-03-30 2014-11-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
CN101437519A (zh) * 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
US20090286803A1 (en) 2006-04-07 2009-11-19 Manley Paul W Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
EP2012789B1 (en) 2006-04-14 2013-09-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (AMD)
JP5161072B2 (ja) * 2006-04-27 2013-03-13 Ｍｓｄ株式会社 オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
PE20080993A1 (es) 2006-06-27 2008-10-06 Takeda Pharmaceutical Compuestos ciclicos fusionados como moduladores del receptor gpr40
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
JPWO2008001886A1 (ja) * 2006-06-30 2009-11-26 協和発酵キリン株式会社 オーロラ（Ａｕｒｏｒａ）阻害剤
MX2008016523A (es) * 2006-06-30 2009-01-19 Astrazeneca Ab Derivados de pirimidina utiles en el tratamiento de cancer.
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
WO2008021038A2 (en) * 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
US7832809B2 (en) * 2006-08-11 2010-11-16 Schlumberger Technology Corporation Degradation assembly shield
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008053812A1 (fr) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Dérivé de cyanopyridine et son utilisation médicale
JP2010509231A (ja) * 2006-11-02 2010-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリジンおよびアミノピリミジン
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
MX2009006690A (es) * 2006-12-19 2009-07-31 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
KR20090094073A (ko) * 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
EA020749B1 (ru) * 2006-12-29 2015-01-30 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5,6-замещенные пиримидины
KR20090108124A (ko) 2007-02-06 2009-10-14 노파르티스 아게 Ｐｉ 3-키나제 억제제 및 그의 사용 방법
TW200901975A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
CA2680029A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
ES2435997T3 (es) * 2007-03-09 2013-12-26 Vertex Pharmaceuticals, Inc. Aminopirimidinas útiles como inhibidores de las proteínas cinasas
EP2134709A1 (en) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
JP2010522194A (ja) * 2007-03-20 2010-07-01 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害薬として有用なアミノピリミジン
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
MX2009011059A (es) 2007-04-13 2009-11-26 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.
US20100204246A1 (en) * 2007-04-18 2010-08-12 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo (4,5-b) pyridine derivatives and their use for the treatment of cancer
AP2009005010A0 (en) 2007-04-18 2009-10-31 Pfizer Prod Inc Sulfonyl amide derivatives for the treatment of abnormal cell growth
AU2008247594A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2008247595A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2008247592A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ATE521609T1 (de) * 2007-05-04 2011-09-15 Astrazeneca Ab Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
WO2009008992A2 (en) * 2007-07-06 2009-01-15 Osi Pharmaceuticals Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
WO2009007753A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
JP5282091B2 (ja) * 2007-07-25 2013-09-04 ブリストル−マイヤーズ スクイブ カンパニー トリアジンキナーゼ阻害剤
WO2009013545A2 (en) * 2007-07-26 2009-01-29 Astrazeneca Ab Chemical compounds
TW200906818A (en) * 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
CA2694499A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
EP3078662A1 (en) 2007-09-21 2016-10-12 Array Biopharma, Inc. Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
PL2214487T3 (pl) 2007-10-11 2014-04-30 Glaxosmithkline Llc NOWE INHIBITORY sEH I ICH ZASTOSOWANIE
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
MX2010009268A (es) * 2008-02-21 2010-09-14 Schering Corp Compuestos que son inhibidores de erk.
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
ES2545731T3 (es) 2008-04-21 2015-09-15 Taigen Biotechnology Co., Ltd. Compuestos heterocíclicos
US8844033B2 (en) 2008-05-27 2014-09-23 The Trustees Of Columbia University In The City Of New York Systems, methods, and media for detecting network anomalies using a trained probabilistic model
CN102119157A (zh) * 2008-06-11 2011-07-06 阿斯利康(瑞典)有限公司 用于治疗癌症和骨髓增生性疾病的三环2，4-二氨基-l，3，5-三嗪衍生物
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
AR073354A1 (es) * 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
KR20110050549A (ko) * 2008-09-03 2011-05-13 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 이를 포함하는 제약 제제
CN102405284B (zh) * 2008-09-05 2016-01-20 新基阿维罗米克斯研究公司 设计不可逆抑制剂的算法
CN102264728B (zh) 2008-09-15 2015-02-04 加利福尼亚大学董事会 用于调节ire1、src和abl活性的方法和组合物
TW201018693A (en) * 2008-09-30 2010-05-16 Astrazeneca Ab Chemical compounds 496-1p
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
US9023834B2 (en) 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
US8524707B2 (en) * 2008-12-19 2013-09-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
US8809343B2 (en) 2008-12-26 2014-08-19 Fudan University Pyrimidine derivative, preparation method and use thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
DK2401267T3 (en) * 2009-02-27 2014-03-10 Ambit Biosciences Corp JAK-kinase modulating quinazoline derivatives AND THEIR APPLICATION IN PROCESSES
CA2660962A1 (en) 2009-03-31 2010-09-30 Astellas Pharma Inc. Novel pharmaceutical composition for treatment of schizophrenia
US8399663B2 (en) 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
BRPI1010881A2 (pt) * 2009-06-08 2016-05-31 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas.
KR20120034726A (ko) * 2009-06-08 2012-04-12 아브락시스 바이오사이언스, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
WO2010144522A1 (en) * 2009-06-09 2010-12-16 Abraxis Bioscience, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
CN102573482A (zh) * 2009-06-09 2012-07-11 加利福尼亚资本权益有限责任公司 苯乙烯基-三嗪衍生物及其治疗应用
JP2012529517A (ja) * 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
JP5785940B2 (ja) * 2009-06-09 2015-09-30 アブラクシス バイオサイエンス， エルエルシー トリアジン誘導体類及びそれらの治療応用
CA2763730A1 (en) * 2009-06-18 2010-12-23 Cellzome Limited Heterocyclylaminopyrimidines as kinase inhibitors
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
CN105063001A (zh) * 2009-09-16 2015-11-18 新基阿维罗米克斯研究公司 蛋白激酶复合物和含有该复合物的药物组合物以及它们的用途
KR101859032B1 (ko) * 2009-11-13 2018-05-18 인튜어티브 서지컬 오퍼레이션즈 인코포레이티드 여분의 닫힘 메커니즘을 구비한 단부 작동기
WO2011090738A2 (en) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
SA111320200B1 (ar) * 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
CA2788774A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2571359A4 (en) * 2010-05-20 2013-10-23 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
RU2528386C2 (ru) 2010-05-21 2014-09-20 Кемилиа Аб Новые производные пиримидина
RS54865B1 (sr) 2010-06-04 2016-10-31 Hoffmann La Roche Derivati aminopirimidina kao modulatori lrrk2
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
DK2598482T3 (en) 2010-07-29 2018-06-14 Oryzon Genomics Sa ARYLCYCLOPROPYLAMINE-BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE
EP2663553B1 (en) * 2010-09-01 2015-08-26 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
US20130225615A1 (en) * 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
CA2809994A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
EP2611789A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2611502A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030914A1 (en) * 2010-09-01 2012-03-08 Ambit Boisciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
AU2011296046B2 (en) * 2010-09-01 2015-05-14 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
SG189043A1 (en) 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
ES2587864T3 (es) 2011-03-24 2016-10-27 Noviga Research Ab Derivados de pirimidina
KR20140062079A (ko) 2011-08-25 2014-05-22 에프. 호프만-라 로슈 아게 세린/트레오닌 pak1 억제제
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2575710T3 (es) 2011-09-22 2016-06-30 Pfizer Inc Derivados de pirrolopirimidina y purina
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GEP20166432B (en) 2011-09-27 2016-02-10 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US8815877B2 (en) 2011-12-22 2014-08-26 Genentech, Inc. Serine/threonine kinase inhibitors
US9447051B2 (en) * 2012-02-17 2016-09-20 Abbvie Inc. Diaminopyrimidines and uses thereof
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
CN104334545A (zh) 2012-03-16 2015-02-04 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
BR112014026703B1 (pt) 2012-04-24 2022-10-25 Vertex Pharmaceuticals Incorporated Inibidores de dna-pk e seus usos, composição farmacêutica e seus usos, e método de sensibilização de uma célula
US9296725B2 (en) * 2012-05-24 2016-03-29 Cellzome Limited Heterocyclyl pyrimidine analogues as TYK2 inhibitors
CN104797267A (zh) 2012-06-26 2015-07-22 德玛医药 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法
EP2872501B1 (en) * 2012-07-10 2016-06-01 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
BR112015005489B1 (pt) * 2012-09-19 2022-07-12 Taiho Pharmaceutical Co., Ltd. Composição farmacêutica para administração oral com dissolução e/ou absorção aperfeiçoadas
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103202843B (zh) * 2012-12-31 2015-04-29 刘强 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
CN103191120B (zh) * 2012-12-31 2015-11-25 刘强 一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途
CN103059002B (zh) * 2012-12-31 2015-04-22 中山大学 具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用
CN103910716A (zh) * 2013-01-07 2014-07-09 华东理工大学 2,4-二取代-环烷基[d]嘧啶类化合物及其用途
PT3527563T (pt) 2013-03-12 2021-12-09 Vertex Pharma Inibidores de adn-pk
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP2968322B1 (en) 2013-03-15 2018-12-26 The Trustees of Columbia University in the City of New York Map kinase modulators and uses thereof
CA2907726A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
WO2015028848A1 (en) * 2013-09-02 2015-03-05 Piramal Enterprises Limited Bicyclic heterocyclic compounds as multi-kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
ES2836325T3 (es) 2014-03-13 2021-06-24 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
MX2016012574A (es) 2014-03-28 2017-09-26 Calitor Sciences Llc Compuestos heteroarilo sustituidos y metodos de uso.
PT3125883T (pt) 2014-04-04 2020-10-12 Iomet Pharma Ltd Derivados de indol para utilização na medicina
CA2945263A1 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN105367555B (zh) * 2014-08-07 2019-06-25 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AR103264A1 (es) 2014-12-23 2017-04-26 Axikin Pharmaceuticals Inc Derivados de 3,5-aminopirazol como inhibidores de quinasa rc
WO2016123627A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
AU2016247858B2 (en) 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
AU2016267141B2 (en) 2015-05-28 2020-04-16 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
JP2018135268A (ja) * 2015-06-05 2018-08-30 大日本住友製薬株式会社 新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
CA3119019C (en) * 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
CN105399695B (zh) * 2015-12-11 2019-04-19 浙江大学 三嗪类化合物及其制备方法和用途
CN105503754B (zh) * 2015-12-11 2017-11-17 浙江大学 2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
CN105384702B (zh) * 2015-12-11 2018-04-10 浙江大学 三取代均三嗪类化合物及其制备方法
EP3390387B1 (en) 2015-12-18 2021-11-17 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
US10822311B2 (en) 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
CN108779119B (zh) * 2016-03-25 2022-02-08 传入制药公司 嘧啶及其变体、及其用途
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
WO2018064092A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
US10968227B2 (en) * 2016-11-08 2021-04-06 Vanderbilt University Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN108239071B (zh) * 2016-12-27 2020-12-04 沈阳药科大学 酰胺及硫代酰胺类衍生物及其制备方法和应用
FR3064275B1 (fr) 2017-03-21 2019-06-07 Arkema France Procede de chauffage et/ou climatisation d'un vehicule
EA201992764A1 (ru) 2017-05-30 2020-04-29 Басф Се Пиридиновые и пиразиновые соединения
SG11201911615WA (en) 2017-06-05 2020-01-30 Ptc Therapeutics Inc Compounds for treating huntington's disease
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP2020525525A (ja) * 2017-06-30 2020-08-27 ベイジン タイド ファーマシューティカル カンパニー リミテッドＢｅｉｊｉｎｇ Ｔｉｄｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS
EP3675860B1 (en) * 2017-08-28 2023-03-08 Zhihong, Chen Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
LT3672965T (lt) 2017-10-27 2022-10-10 Theravance Biopharma R&D Ip, Llc Pirimidino junginys, kaip jak kinazės inhibitorius
KR20200090198A (ko) * 2017-11-23 2020-07-28 바이오메드 엑스 게엠베하 트로포미오신 수용체 키나제 A(TrkA) 저해제로서의 피리미딘 유도체
WO2019113311A1 (en) * 2017-12-06 2019-06-13 Ludwig Institute For Cancer Research Ltd Methods of treating cancer with plk4 inhibitors
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3810132A4 (en) * 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
WO2020108613A1 (zh) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
AR118767A1 (es) 2019-04-24 2021-10-27 Theravance Biopharma R&D Ip Llc Pirimidinas sustituidas como inhibidores de jak y su uso para el tratamiento de enfermedades inflamatorias o autoinmunes cutáneas
JP7470713B2 (ja) 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｊａｋキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
WO2021019514A1 (en) * 2019-08-01 2021-02-04 Integral Biosciences Pvt. Ltd. Heterocyclic compounds as kinase inhibitor and uses thereof
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
CN114728962A (zh) 2019-09-18 2022-07-08 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
CN110483493A (zh) * 2019-09-19 2019-11-22 广东工业大学 一种二唑类衍生物及其制备方法和应用
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
US20240199613A1 (en) * 2021-03-17 2024-06-20 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
AU2022243600A1 (en) * 2021-03-26 2023-10-12 Sumitomo Pharma Oncology, Inc. Alk-5 inhibitors and uses thereof
JP2024521657A (ja) 2021-05-11 2024-06-04 オリック ファーマシューティカルズ，インク． ポロ様キナーゼ４阻害剤
US11932648B2 (en) 2021-06-28 2024-03-19 Blueprint Medicines Corporation CDK2 inhibitors
KR102692529B1 (ko) * 2021-07-01 2024-08-08 한국원자력의학원 Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물
CN116354938B (zh) * 2021-12-28 2024-02-20 沈阳药科大学 一类喹唑啉衍生物与其类似物的制备方法及应用
CN114276302B (zh) * 2022-01-11 2023-07-25 山东百启生物医药有限公司 一种制备2,4-二氨基喹唑啉衍生物的方法
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
CN117736198A (zh) * 2022-09-21 2024-03-22 科辉智药生物科技(深圳)有限公司 大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
CN115403568B (zh) * 2022-09-21 2023-09-29 中山大学 一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18436A (en) * 1857-10-20 And saml
US3133081A (en) 1964-05-12 J-aminoindazole derivatives
US2585906A (en) 1952-02-12 Quaternary salts of pyrimdjines
US3935183A (en) 1970-01-26 1976-01-27 Imperial Chemical Industries Limited Indazole-azo phenyl compounds
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3998951A (en) * 1974-03-13 1976-12-21 Fmc Corporation Substituted 2-arylquinazolines as fungicides
DE2458965C3 (de) 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
MA18829A1 (fr) 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DOP1981004033A (es) 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
SE8102193L (sv) 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
SE8102194L (sv) 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
JPS58124773A (ja) 1982-01-20 1983-07-25 Mitsui Toatsu Chem Inc ５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤
EP0136976A3 (de) 1983-08-23 1985-05-15 Ciba-Geigy Ag Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
DE3725638A1 (de) 1987-08-03 1989-02-16 Bayer Ag Neue aryloxy (bzw. thio)aminopyrimidine
JPH0532662A (ja) 1990-11-09 1993-02-09 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5597920A (en) 1992-04-30 1997-01-28 Neurogen Corporation Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (ja) * 1992-05-07 1994-03-08 Nissan Chem Ind Ltd 置換ピラゾール誘導体および農園芸用殺菌剤
JP3588116B2 (ja) 1993-10-01 2004-11-10 ノバルティス アクチェンゲゼルシャフト 薬理活性のピリミジンアミン誘導体およびその製造方法
JPH10509708A (ja) 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
JPH11512390A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキシレートおよび関連化合物ならびに炎症状態を処置するための方法
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
JPH10130150A (ja) 1996-09-05 1998-05-19 Dainippon Pharmaceut Co Ltd 酢酸アミド誘導体からなる医薬
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
EP0929553B1 (en) 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
WO1998016502A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
CA2306692C (en) 1997-10-10 2010-09-21 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
JP2000026421A (ja) 1998-01-29 2000-01-25 Kumiai Chem Ind Co Ltd ジアリ―ルスルフィド誘導体及び有害生物防除剤
NZ506417A (en) 1998-02-17 2003-05-30 Tularik Inc Anti-viral pyrimidine derivatives
CN1297354A (zh) 1998-03-16 2001-05-30 西托维亚公司 二肽卡斯帕酶抑制剂及其用途
WO1999062518A1 (en) 1998-06-02 1999-12-09 Osi Pharmaceuticals, Inc. PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
WO2000003901A1 (de) * 1998-07-16 2000-01-27 Continental Teves Ag & Co. Ohg Verfahren und vorrichtung zum ermitteln von kritischen fahrzuständen bei im fahrbetrieb befindlichen fahrzeugen
WO2000011003A1 (en) 1998-08-21 2000-03-02 Du Pont Pharmaceuticals Company ISOXAZOLO[4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
ES2241324T3 (es) * 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
WO2000042029A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
JP4673977B2 (ja) 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
AU781849C (en) * 1999-06-17 2006-03-02 Synta Pharmaceuticals Corp. Inhibitors of IL-12 production
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
JP2003531103A (ja) 1999-08-12 2003-10-21 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−ＪＵＮＮ−末端キナーゼ（ＪＮＫ）および他のタンパク質キナーゼの阻害剤
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
CN1402720A (zh) 1999-11-30 2003-03-12 辉瑞产品公司 用作免疫抑制剂的2,4－二氨基嘧啶化合物
IL149935A0 (en) 1999-12-02 2002-11-10 Osi Pharm Inc Compounds specific to adenosine a1, a2a and a3 receptors and uses thereof
MY125768A (en) 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU782775B2 (en) 2000-02-05 2005-08-25 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of ERK
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
MXPA02010222A (es) 2000-04-18 2003-05-23 Agouron Pharma Pirazoles para inhibir proteina cinasa.
JP3890184B2 (ja) * 2000-05-15 2007-03-07 Ｎｅｃパーソナルプロダクツ株式会社 電源装置及びその電力制御方法、情報処理機器
MXPA02011974A (es) 2000-06-28 2004-09-06 Astrazeneca Ab Derivados de quinazolina sustituidos y su uso como inhibidores.
JP2004507526A (ja) 2000-08-31 2004-03-11 ファイザー・プロダクツ・インク ピラゾール誘導体及びそのプロテインキナーゼ阻害剤としての使用
EP1317448B2 (en) 2000-09-15 2011-05-04 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6495582B1 (en) 2000-09-15 2002-12-17 Vertex Pharmaceuticals Incorporated Isoxazole compositions useful as inhibitors of ERK
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004509876A (ja) 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４−アミノ−キナゾリン
US6641579B1 (en) 2000-09-29 2003-11-04 Spectrasonics Imaging, Inc. Apparatus and method for ablating cardiac tissue
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
DE10061863A1 (de) 2000-12-12 2002-06-13 Basf Ag Verfahren zur Herstellung von Triethylendiamin (TEDA)
AU2002228922A1 (en) 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP4160395B2 (ja) 2000-12-21 2008-10-01 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1373257B9 (en) 2001-03-29 2008-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
DE60214701T2 (de) 2001-04-13 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
WO2002085909A1 (en) 2001-04-20 2002-10-31 Vertex Pharmaceuticals Incorporated 9-deazaguanine derivatives as inhibitors of gsk-3
JP4316893B2 (ja) 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
EP1399440B1 (en) 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
ATE337312T1 (de) 2001-07-03 2006-09-15 Vertex Pharma Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
WO2003026665A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US6569499B2 (en) 2001-10-02 2003-05-27 Xerox Corporation Apparatus and method for coating photoreceptor substrates
US20030199526A1 (en) 2001-12-07 2003-10-23 Deborah Choquette Pyrimidine-based compounds useful as GSK-3 inhibitors
ATE466580T1 (de) 2002-03-15 2010-05-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) 2002-03-15 2010-07-01 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
DE60314603T2 (de) 2002-03-15 2008-02-28 Vertex Pharmaceuticals Inc., Cambridge Zusammensetzungen brauchbar als protein-kinase-inhibitoren
US7179826B2 (en) 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20030207873A1 (en) 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003247959B2 (en) 2002-07-09 2010-07-29 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
EP1532145B1 (en) 2002-08-02 2006-09-13 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
MX2009006690A (es) 2006-12-19 2009-07-31 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.

Also Published As

Publication number Publication date
JP2004517894A (ja) 2004-06-17
US20130096128A1 (en) 2013-04-18
HUP0400908A2 (hu) 2004-07-28
CA2432131C (en) 2008-07-08
US20140187772A1 (en) 2014-07-03
MXPA03005612A (es) 2003-10-06
EP1355905B1 (en) 2007-02-21
WO2002059112A2 (en) 2002-08-01
JP2004516292A (ja) 2004-06-03
MXPA03005611A (es) 2003-10-06
HK1060557A1 (en) 2004-08-13
DK1355905T3 (da) 2007-06-18
ES2265446T3 (es) 2007-02-16
PT1345922E (pt) 2006-09-29
US20030022885A1 (en) 2003-01-30
WO2002050066A2 (en) 2002-06-27
WO2002068415A1 (en) 2002-09-06
WO2002059111A2 (en) 2002-08-01
WO2002062789A1 (en) 2002-08-15
NO20032703D0 (no) 2003-06-13
MXPA03005606A (es) 2003-10-06
JP2008222719A (ja) 2008-09-25
US6664247B2 (en) 2003-12-16
US20080287444A1 (en) 2008-11-20
TWI313269B (en) 2009-08-11
EP1345928B1 (en) 2007-02-14
DE60119777D1 (de) 2006-06-22
NZ526474A (en) 2005-10-28
CN100406454C (zh) 2008-07-30
EP1702920B1 (en) 2011-10-12
JP2008260767A (ja) 2008-10-30
CN100340555C (zh) 2007-10-03
JP2004516291A (ja) 2004-06-03
SI1355905T1 (sl) 2007-08-31
HK1060349A1 (en) 2004-08-06
WO2002059111A3 (en) 2003-01-09
ES2375491T3 (es) 2012-03-01
EP1353916B1 (en) 2006-09-20
US20030055068A1 (en) 2003-03-20
US20030004161A1 (en) 2003-01-02
NO328501B1 (no) 2010-03-01
KR100909665B1 (ko) 2009-07-29
ATE326462T1 (de) 2006-06-15
ATE354573T1 (de) 2007-03-15
AU2002231166B2 (en) 2008-02-21
DE60123283T2 (de) 2007-04-12
US20030105090A1 (en) 2003-06-05
DE60126828D1 (de) 2007-04-05
EP1702920A1 (en) 2006-09-20
JP2004517927A (ja) 2004-06-17
EP1345926B1 (en) 2006-05-17
ES2266095T3 (es) 2007-03-01
DE60126828T2 (de) 2007-11-08
HUP0400908A3 (en) 2010-03-29
US20040167141A1 (en) 2004-08-26
EP1345926A2 (en) 2003-09-24
CY1106297T1 (el) 2011-10-12
DE60119775T2 (de) 2007-05-10
JP4210520B2 (ja) 2009-01-21
JP4160389B2 (ja) 2008-10-01
AR042169A1 (es) 2005-06-15
CA2432303C (en) 2010-04-13
PL210066B1 (pl) 2011-11-30
KR20030061465A (ko) 2003-07-18
HK1061389A1 (en) 2004-09-17
EP1345927A1 (en) 2003-09-24
AU2002246754B2 (en) 2006-06-08
JP4234435B2 (ja) 2009-03-04
NO20032670D0 (no) 2003-06-12
CA2432223A1 (en) 2002-09-06
HK1062433A1 (en) 2004-11-05
NO20032736D0 (no) 2003-06-16
DE60119775D1 (de) 2006-06-22
CA2432222C (en) 2008-07-29
MXPA03005610A (es) 2003-10-06
KR20030061468A (ko) 2003-07-18
IL156408A0 (en) 2004-01-04
PT1355905E (pt) 2007-05-31
PL363244A1 (en) 2004-11-15
ES2272567T3 (es) 2007-05-01
RU2355688C2 (ru) 2009-05-20
DE60120219T2 (de) 2007-04-12
JP2004518743A (ja) 2004-06-24
WO2002050066A3 (en) 2003-01-23
NO20032671L (no) 2003-08-18
JP2013213068A (ja) 2013-10-17
WO2002057259A2 (en) 2002-07-25
IL156369A (en) 2011-02-28
HK1060346A1 (en) 2004-08-06
WO2002050065A2 (en) 2002-06-27
KR100947185B1 (ko) 2010-03-15
JP2005097322A (ja) 2005-04-14
CA2432222A1 (en) 2002-08-15
AU2006201267B2 (en) 2010-07-29
HUP0400639A2 (hu) 2004-06-28
RU2003122209A (ru) 2005-02-10
EP1355905A1 (en) 2003-10-29
CN100436452C (zh) 2008-11-26
CN1549812A (zh) 2004-11-24
ATE528303T1 (de) 2011-10-15
WO2002066461A1 (en) 2002-08-29
NO20032704L (no) 2003-08-21
US8697698B2 (en) 2014-04-15
MXPA03005609A (es) 2003-10-06
US7427681B2 (en) 2008-09-23
CA2432129A1 (en) 2002-07-25
IL156389A (en) 2011-01-31
CN1486311A (zh) 2004-03-31
JP2004518703A (ja) 2004-06-24
US8304414B2 (en) 2012-11-06
JP4160395B2 (ja) 2008-10-01
TW200716617A (en) 2007-05-01
JP5249842B2 (ja) 2013-07-31
CA2432799A1 (en) 2002-06-27
DE60119774D1 (de) 2006-06-22
CN1487933A (zh) 2004-04-07
US6989385B2 (en) 2006-01-24
NZ526473A (en) 2005-06-24
CA2432872A1 (en) 2002-06-27
CA2432129C (en) 2008-08-26
BR0116411A (pt) 2003-11-11
US20040157893A1 (en) 2004-08-12
DE60119774T2 (de) 2007-05-16
DE60119777T2 (de) 2007-05-03
US20040214814A1 (en) 2004-10-28
EP1345927B1 (en) 2006-05-17
HUP0400639A3 (en) 2010-03-29
EP1345928A2 (en) 2003-09-24
CA2432132A1 (en) 2002-08-01
NO20032670L (no) 2003-08-15
CA2432223C (en) 2008-05-20
WO2002059112A3 (en) 2003-02-06
AR042398A1 (es) 2005-06-22
EP1353916A2 (en) 2003-10-22
BR0116493A (pt) 2003-09-30
AP2003002825A0 (en) 2003-09-30
HUP0400641A2 (hu) 2004-06-28
MXPA03005605A (es) 2003-10-06
CA2432872C (en) 2008-09-23
CA2432131A1 (en) 2002-08-01
JP4160392B2 (ja) 2008-10-01
ES2280313T3 (es) 2007-09-16
IL156368A0 (en) 2004-01-04
ATE353890T1 (de) 2007-03-15
CA2432303A1 (en) 2002-08-29
IL209827A0 (en) 2011-02-28
ATE326461T1 (de) 2006-06-15
DK1353916T3 (da) 2007-01-29
CN102250071A (zh) 2011-11-23
ATE326463T1 (de) 2006-06-15
DE60126658T2 (de) 2007-11-22
JP2008247920A (ja) 2008-10-16
WO2002057259A3 (en) 2003-04-24
NZ526471A (en) 2005-08-26
AU2002255452B2 (en) 2006-06-08
JP2009286805A (ja) 2009-12-10
AU2002234047A1 (en) 2002-07-01
CA2432799C (en) 2008-08-19
AP1588A (en) 2006-03-06
IL156369A0 (en) 2004-01-04
KR20030061467A (ko) 2003-07-18
AP2003002816A0 (en) 2003-06-30
AU3116602A (en) 2002-07-01
IL156407A0 (en) 2004-01-04
NO330527B1 (no) 2011-05-09
US20030078275A1 (en) 2003-04-24
US7087603B2 (en) 2006-08-08
AR040925A1 (es) 2005-04-27
NZ526470A (en) 2006-03-31
NO20032736L (no) 2003-08-18
SI1353916T1 (sl) 2007-02-28
US6653300B2 (en) 2003-11-25
US6656939B2 (en) 2003-12-02
PL210414B1 (pl) 2012-01-31
CA2432132C (en) 2008-07-29
HUP0400842A2 (hu) 2004-07-28
PT1353916E (pt) 2007-01-31
NO20032704D0 (no) 2003-06-13
JP2009155352A (ja) 2009-07-16
KR100875091B1 (ko) 2008-12-22
JP2008201808A (ja) 2008-09-04
CN100408573C (zh) 2008-08-06
HK1060347A1 (en) 2004-08-06
KR20030061466A (ko) 2003-07-18
NZ526469A (en) 2005-10-28
EP1345922B1 (en) 2006-05-31
ATE340172T1 (de) 2006-10-15
US7625913B2 (en) 2009-12-01
JP2008189687A (ja) 2008-08-21
PL363246A1 (en) 2004-11-15
EP2264028A1 (en) 2010-12-22
NO20032671D0 (no) 2003-06-12
HUP0400638A2 (hu) 2004-06-28
JP2008247921A (ja) 2008-10-16
KR20030061858A (ko) 2003-07-22
DE60119776D1 (de) 2006-06-22
US20040132781A1 (en) 2004-07-08
US20030004164A1 (en) 2003-01-02
US20090312543A1 (en) 2009-12-17
CN1486312A (zh) 2004-03-31
JP2004519479A (ja) 2004-07-02
EP1345922A1 (en) 2003-09-24
US20030036543A1 (en) 2003-02-20
ES2265452T3 (es) 2007-02-16
AR042397A1 (es) 2005-06-22
ATE326460T1 (de) 2006-06-15
DK1345922T3 (da) 2006-09-18
DE60120219D1 (de) 2006-07-06
ES2265450T3 (es) 2007-02-16
DE60119776T2 (de) 2007-05-16
MY140377A (en) 2009-12-31
MXPA03005607A (es) 2003-10-06
AU2001297619B2 (en) 2006-06-08
US7982037B2 (en) 2011-07-19
KR20030061463A (ko) 2003-07-18
KR20030061464A (ko) 2003-07-18
AU2006201267A1 (en) 2006-04-27
US7531536B2 (en) 2009-05-12
JP2004517926A (ja) 2004-06-17
NZ526472A (en) 2004-04-30
WO2002050065A3 (en) 2002-10-24
NO328537B1 (no) 2010-03-15
JP2008189682A (ja) 2008-08-21
EP1345929B1 (en) 2006-05-17
EP1345925B1 (en) 2006-05-17
NZ526468A (en) 2004-03-26
US6653301B2 (en) 2003-11-25
CN1486310A (zh) 2004-03-31
EP1345929A2 (en) 2003-09-24
HK1062565A1 (en) 2004-11-12
EP1345925A2 (en) 2003-09-24
DE60123283D1 (de) 2006-11-02
HUP0400641A3 (en) 2010-03-29
IL156389A0 (en) 2004-01-04
DE60126658D1 (de) 2007-03-29
ATE327989T1 (de) 2006-06-15
US6727251B2 (en) 2004-04-27
KR100889246B1 (ko) 2009-03-19
KR100843114B1 (ko) 2008-07-02
KR20030061857A (ko) 2003-07-22
US20050038023A1 (en) 2005-02-17
HK1059776A1 (en) 2004-07-16
NZ526475A (en) 2005-06-24
MXPA03005608A (es) 2003-10-06
TWI290551B (en) 2007-12-01

Similar Documents

Publication Publication Date Title
NO20031188D0 (no) Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20032670D0 (no) Pyrazolforbindelser nyttige som proteinkinaseinhibitorer
NO20041887L (no) Benzomidazoler anvendelige som proteinkinase-inhibitorer
NO20030779D0 (no) Kondenserte pyrazolderivater som er proteinkinase-inhibitorer
DK1337527T3 (da) Indolylmaleinimidderivater som proteinkinase C-inhibitorer
DK1317448T4 (da) Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees